Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 8/20 | 0.71 |
| ▸ | KMO | O15229 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | NOS3 | P29474 | 4/20 | 0.56 |
| ▸ | NOS1 | P29475 | 4/20 | 0.56 |
| ▸ | NOS2 | P35228 | 4/20 | 0.56 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29958110 | 1.00 | IDO1 (0.71) | IDO1KMOHPGDKMT2AMEN1 | |
| SCHEMBL4414360 | 0.88 | HPGD (0.64) | IDO1KMOHPGDKMT2AMEN1 | |
| SCHEMBL2953606 | 0.87 | KMO (0.74) | IDO1KMOKMT2AMEN1NOS3 | |
| SCHEMBL29670895 | 0.87 | KMO (0.74) | IDO1KMOKMT2AMEN1NOS3 | |
| SCHEMBL655852 | 0.84 | HPGD (0.66) | IDO1KMOHPGD | |
| SCHEMBL16250472 | 0.82 | HPGD (0.64) | HPGDKMT2AMEN1ALDH1A1 | |
| SCHEMBL4426587 | 0.82 | HPGD (0.64) | IDO1KMOHPGDKMT2AMEN1 | |
| SCHEMBL4425116 | 0.82 | KMT2A (0.66) | IDO1KMOKMT2AMEN1NOS3 | |
| SCHEMBL23964619 | 0.81 | IDO1 (0.69) | IDO1KMONOS3NOS1NOS2 | |
| SCHEMBL4420785 | 0.81 | HPGD (0.56) | IDO1HPGDKMT2AALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4308228-A1 | PLASMA KALLIKREIN INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2024-01-24 | — | — | EP | disclosed |
| WO-2022197756-A1 | PLASMA KALLIKREIN INHIBITORS | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| US-8293775-B2 | Benzoxazolone derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2012-10-23 | — | — | US | disclosed |
| EP-1756071-B1 | BENZOXAZOLONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB PHARMA SA (BE) | 2009-08-26 | — | — | EP | disclosed |
| US-20070299118-A1 | Benzoxazolone Derivatives, Processes For Preparing Them And Their Uses | UCB, S.A. (BE) | 2007-12-27 | — | — | US | disclosed |
| EP-1756071-A1 | BENZOXAZOLONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2007-02-28 | — | — | EP | disclosed |
| WO-2007022257-A2 | MONOCYCLIC AND BICYCLIC COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| WO-2005118561-A1 | BENZOXAZOLONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299118-A1 | Benzoxazolone Derivatives, Processes For Preparing Them And Their Uses | PARK7, SNCA, GABRA5 | IDO1 1662/4885KMO 67/4885HPGD 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.